When it comes to diabetes care, there’s a minimum standard expected from eye care professionals (ECPs). According to a recent study, many ECPs’ diabetes protocols are not meeting the current National Eye Institute of Clinical Excellence’s (NICE) guidelines. Here’s what the research shows.
The Research & Findings
The 5-year, single-center audit of a general practice included 50 records of type 2 diabetes patients. The results were:
- 16% of individuals underwent retinal screening that adhered to NICE guidelines.
- Of those that did not undergo retinal screening:
- 60% went more than three months between their initial diagnosis and first screening.
- 65% had a screening interval greater than one year.
The study authors cited these long lapses in screenings as the main reasons for failing.
In order to meet the NICE guidelines, patients identified with diabetes should get their first retinal screening within 3 months. NICE recommendations say:
“explain that it will help them to keep their eyes healthy and help to [avoid] problems with their vision. Explain that the screening service is effective at identifying problems so that they can be [addressed] early.”
While this is out of most ECPs’ hands, it drives home the idea of building a network for caring for patients with diabetes. Read the blog about getting involved in diabetes care.
For ECPs, there’s another way to get a bit more involved in helping patients protect their eyes. EyePromise® DVS is a research backed eye health nutraceutical designed to support the long-term eye health of patients with diabetes. This formula was crafted with ingredients that have been proven to interfere with the way diabetes affects the eyes. After a 6-month clinical trial, participants experienced:
- Improved macular pigment optical density (MPOD)
- Improved color vision
- Increased contrast sensitivity
- Reduced blood pressure and cholesterol
- No impact on blood sugar levels
Additional clinical support is provided in a case study conducted by Dr. Nate Lighthizer at the University of Oklahoma. Ultimately, EyePromise DVS demonstrated positive objective outcomes via ffERG for a patient with diabetes.
Overall, the clinical audit reveals a gap in diabetes care that needs improvement. The first step is creating a diabetes care network, then stressing the importance of prompt and regular eye health screenings. Additionally, adding a nutraceutical like EyePromise DVS can help you do even more for patients with diabetes.